8-K ·Filed Jul 7, 2026
8-K context-dependent: Items 5.02
Actionable Insight • Neutral
No immediate catalyst from this filing; monitor for any strategic or operational changes under new CEO. The internal succession limits disruption risk.
Final — all horizons settled through T+60d
SPRY ▼ -49.14% at T+60d
NEUTRAL call -49.14% · α vs SPY -51.63% · entry $8.10 → $4.12
T+1d
-2.72%
call -2.72% · α -3.56%
$7.88
settled 4mo ago
T+5d
-6.05%
call -6.05% · α -6.91%
$7.61
settled 3mo ago
T+20d
-33.83%
call -33.83% · α -37.10%
$5.36
settled 3mo ago
T+60d
-49.14%
call -49.14% · α -51.63%
$4.12
settled 26d ago
Price Chart
Loading chart...
Executive Summary
ARS Pharmaceuticals announced the termination without cause of CEO Richard Lowenthal, effective immediately, and appointed President Donn Casale as his replacement and to the Board. The internal promotion suggests continuity, making this a routine leadership transition with limited immediate stock impact.
Key Facts
- CEO Richard Lowenthal terminated without cause, effective July 6, 2026
- President Donn Casale appointed as CEO and Class III director, effective July 7, 2026
- Casale's biographical information incorporated by reference from May 13, 2026 8-K
Financial Impact
Not specified
Risk Factors
- Potential strategic shift or cultural changes under new leadership
- Uncertainty around any future management team adjustments
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-297554 |
| Document: 0001193125-26-297554-index-headers.html | 0001193125-26-297554 |
| Document: 0001193125-26-297554-index.html | 0001193125-26-297554 |
| Document: 0001193125-26-297554.txt | 0001193125-26-297554 |
13 reports for SPRY
67% Hit rate @ T+1 Went positive at some point 3 of 3 best @ T+60▲ +32.03%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | 144 | $4.29 $4.18 | ▲ +2.56% | ▲ +3.09% | $4.03 (+6.06%) |
Sep 28, 2026 28d ago | Court Ruling | $4.40 $4.31 | ▼ −2.05% | ▼ −1.84% | $4.03 (−8.41%) |
Sep 16, 2026 5w ago | Court Ruling | $4.15 $4.11 | ▼ −0.96% | ▼ −0.84% | $4.03 (−2.89%) |
Aug 3, 2026 12w ago | Press Release | $5.46 $5.32 | ▼ −2.56% | ▼ −4.37% | $4.03 (−26.19%) |
Jul 17, 2026 14w ago | Court Ruling | $6.44 $6.36 | ▼ −1.24% | ▼ −2.08% | $4.03 (−37.42%) |
Jul 7, 2026 15w ago | 8-K | $8.10 $7.88 | ▼ −2.72% | ▼ −3.56% | $4.03 (−50.25%) |
Jun 12, 2026 19w ago | Insider Cluster | $9.81 $9.70 | ▼ −1.12% | ▼ −0.53% | $4.03 (−58.92%) |
May 15, 2026 23w ago | 8-K | $7.43 $7.30 | ▼ −1.68% | ▼ −1.62% | $4.03 (−45.72%) |
May 15, 2026 23w ago | Press Release | $7.43 $7.30 | ▲ +1.68% | ▲ +1.62% | $4.03 (+45.72%) |
May 13, 2026 23w ago | 8-K | $8.01 $7.94 | ▼ −0.87% | ▼ −1.65% | $4.03 (−49.69%) |
Showing 10 of 13
US Market Status
Market Closed — Opens in 22m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers